112 related articles for article (PubMed ID: 10684437)
1. Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia.
Stein E; Sprecher D; Allenby KS; Tosiello RL; Whalen E; Ripa SR
J Cardiovasc Pharmacol Ther; 1997 Jan; 2(1):7-16. PubMed ID: 10684437
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of cerivastatin: phase IIa dose-ranging and dose-scheduling studies.
Hunninghake DB
Am J Cardiol; 1998 Aug; 82(4B):26J-31J. PubMed ID: 9737643
[TBL] [Abstract][Full Text] [Related]
3. A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia.
Sasaki J; Arakawa K; Yamamoto K; Kobori S; Ageta M; Kono S
Clin Ther; 1998; 20(3):539-48. PubMed ID: 9663369
[TBL] [Abstract][Full Text] [Related]
4. Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety.
Stein E
Am J Cardiol; 1998 Aug; 82(4B):40J-46J. PubMed ID: 9737645
[TBL] [Abstract][Full Text] [Related]
5. [A comparative long-term trial of sodium cerivastatin, a new HMG-CoA reductase inhibitor, in patients presenting with primary hypercholesterolemia].
Sasaki J; Arakawa K; Yamamoto K; Kobori S; Ageta M; Kono S
Rev Med Interne; 1999 Aug; 20 Suppl 3():393s-398s. PubMed ID: 10480191
[TBL] [Abstract][Full Text] [Related]
6. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
Plosker GL; Dunn CI; Figgitt DP
Drugs; 2000 Nov; 60(5):1179-206. PubMed ID: 11129127
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia.
Stein E; Isaacsohn J; Stoltz R; Mazzu A; Liu MC; Lane C; Heller AH
Am J Cardiol; 1999 May; 83(10):1433-6. PubMed ID: 10335757
[TBL] [Abstract][Full Text] [Related]
8. Cerivastatin in primary hyperlipidemia--a multicenter analysis of efficacy and safety.
Stein E
Atherosclerosis; 1998 Sep; 139 Suppl 1():S15-22. PubMed ID: 9811154
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
Insull W; Black D; Dujovne C; Hosking JD; Hunninghake D; Keilson L; Knopp R; McKenney J; Stein E; Troendle AJ
Arch Intern Med; 1994 Nov; 154(21):2449-55. PubMed ID: 7979841
[TBL] [Abstract][Full Text] [Related]
10. Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy.
Dujovne CA; Davidson MH
Am J Med; 1994 Jun; 96(6A):37S-40S. PubMed ID: 8017465
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group.
Insull W; Isaacsohn J; Kwiterovich P; Ra P; Brazg R; Dujovne C; Shan M; Shugrue-Crowley E; Ripa S; Tota R
J Int Med Res; 2000; 28(2):47-68. PubMed ID: 10898118
[TBL] [Abstract][Full Text] [Related]
12. International multicentre comparison of cerivastatin with placebo and simvastatin for the treatment of patients with primary hypercholesterolaemia. International Cerivastatin Study Group.
Betteridge DJ
Int J Clin Pract; 1999 Jun; 53(4):243-50. PubMed ID: 10563066
[TBL] [Abstract][Full Text] [Related]
13. Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor.
Stein EA
Drugs; 1998; 56 Suppl 1():25-31; discussion 33. PubMed ID: 9740538
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of 300 micrograms and 400 micrograms cerivastatin once daily in patients with primary hypercholesterolaemia: a multicentre, randomized, double-blind, placebo-controlled study.
Hanefeld M; Deslypere JP; Ose L; Durrington PN; Farnier M; Schmage N
J Int Med Res; 1999; 27(3):115-29. PubMed ID: 10505301
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind comparison of cerivastatin and lovastatin for treatment of primary hypercholesterolemia.
Yu WC; Chen CH; Tsao HM; Ding YA
Zhonghua Yi Xue Za Zhi (Taipei); 2002 Jun; 65(6):260-7. PubMed ID: 12201566
[TBL] [Abstract][Full Text] [Related]
16. Cerivastatin in the treatment of mixed hyperlipidemia: the RIGHT study. The Cerivastatin Study Group. Cerivastatin Gemfibrozil Hyperlipidemia Treatment.
Farnier M
Am J Cardiol; 1998 Aug; 82(4B):47J-51J. PubMed ID: 9737646
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
Scharnagl H; Winkler K; Mantz S; Baumstark MW; Wieland H; März W
Exp Clin Endocrinol Diabetes; 2004 May; 112(5):269-77. PubMed ID: 15146374
[TBL] [Abstract][Full Text] [Related]
18. Cerivastatin.
Cheng-Lai A
Heart Dis; 2000; 2(1):93-9. PubMed ID: 11728245
[TBL] [Abstract][Full Text] [Related]
19. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Yee HS; Fong NT
Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of cerivastatin in primary hypercholesterolemia: a long term comparative titration study with simvastatin.
Leiter LA; Hanna K
Can J Cardiol; 1999 May; 15(5):545-55. PubMed ID: 10350664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
